<DOC>
	<DOCNO>NCT00004026</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . CT-2584 may stop growth prostate cancer stop blood flow tumor . PURPOSE : Randomized phase II trial study effectiveness CT-2584 treating patient metastatic prostate cancer respond previous therapy .</brief_summary>
	<brief_title>CT-2584 Treating Patients With Metastatic Prostate Cancer That Has Not Responded Previous Therapy</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy , safety , pharmacokinetics 2 different treatment schedule CT-2584 patient hormone refractory , metastatic adenocarcinoma prostate . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm : Arm I : Patients receive CT-2584 IV 6 hour daily 3 day every 3 week . Arm II : Patients receive CT-2584 IV 6 hour every 7 day 3 week . Courses repeat every 3 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : Approximately 80 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic adenocarcinoma prostate Refractory hormonal therapy Failed least 1 nonhormonal therapy ( prior radiotherapy allow , constitute nonhormonal therapy ) No CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : 60100 % Life expectancy : Not specify Hematopoietic : No know suspect red blood cell disorder ( e.g. , hereditary spherocytosis , paroxysmal nocturnal hematuria , sickle cell trait , autoimmune hemolytic disorder ) Hepatic : Bilirubin great 1.5 mg/dL No severe liver dysfunction , particularly , impair hepatic synthetic function evidence prolonged prothrombin time otherwise unexplained serum albumin le 3 g/dL Renal : Creatinine great 1.5 mg/dL Cardiovascular : No evidence congestive heart failure No clinically significant cardiac arrhythmia No prior concurrent symptom acute coronary artery disease No significant cardiac valve disease ( e.g. , aortic stenosis , valve prosthesis ) Pulmonary : No prior asthma adulthood require therapy Other : No prior seizure drug relate anaphylactic reaction No history microangiopathy ( e.g. , cavenous hemangioma , prior thrombotic thrombocytopenic purpura ) PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior systemic biologic therapy prostate cancer recover Chemotherapy : At least 4 week since prior chemotherapy ( 12 week strontium89 6 week bicalutamide ) recover Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics No concurrent radiotherapy Surgery : At least 3 week since prior major thoracic abdominal surgery Other : At least 4 week since prior investigational drug ( except bisphosphonates ) recover</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>